Soleno Therapeutics Inc (SLNO NASDAQ) stock market data APIs
$53.041
0(0%)
as of May 18, 2026
Try our APIs with
free plan!
Soleno Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.
Prev. Close
53.041
Open
53.041
High
53.041
Low
53.041
52 wk Range
29.43-90.3199
Market Cap
2 763 M
P/E Ratio
27.4663
Shares Outstanding
52 120 K
Revenue
285 M
EPS
0.59
Beta
-2.217
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Soleno Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Soleno Therapeutics Inc data using free add-ons & libraries
Get Soleno Therapeutics Inc Fundamental Data
Soleno Therapeutics Inc Fundamental data includes:
- Net Revenue: 285 M
- EBITDA: 91 515 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-12
- EPS/Forecast: 0.68
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Soleno Therapeutics Inc News
New
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
Strengthens Neurocrine's rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome Adds recently launched therapy with strong early adopti...
Soleno Merger With Neurocrine Puts Profitability And Valuation In Focus
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Soleno Therapeutics (NasdaqCM:SLNO) has entered into a de...
S&P Futures Climb With All Eyes on Key U.S. Jobs Report
June S&P 500 E-Mini futures (ESM26) are trending up +0.46% this morning as investors shrugged off an exchange of fire between the U.S. and Iran and awaited the release of the key U.S. jobs report. Th...
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKATTM XR (diazoxide chol...
Get Soleno Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
